CONTENTS
ACKNOWLEDGEMENTS...................................................................................................I
1 INTRODUCTION...............................................................................................................................................1
Aim...........................................................................................................................................................................2
Cost-Effectiveness Analysis (CEA)..................................................................................................................2
Coronary Heart Disease (CHD).........................................................................................................................3
TheSWSAHS..........................................................................................................................................................4
Risk Factors..........................................................................................................................................................4
Risk Factors Used in this Analysis...................................................................................................................5
2 PREVIOUS CEAS ON NUTRITION INTERVENTIONS.............................................................................6
Weinstein and Stason (1985)...............................................................................................................................6
Kritiansen, Eggen and Thelle (1991)................................................................................................................8
Crowley, Dunt and Day (1995)..........................................................................................................................9
Hall et al (1988).................................................................................................................................................11
The Interventions in More Detail...................................................................................................................16
Some Key Issues for Each Intervention.................................................................................... 19
3 THE INTERVENTIONS.................................................................................................14
Theinterventiongroups..........................................................................................14
THE INTERVENTIONS IN MORE DETAILS...........................................................................16
4 COST-EFFECTIVENESS ANALYSIS...........................................................................................................21
Effectiveness......................................................................................................................................................21
Cost-effectiveness.............................................................................................................................................29
Sensitivity Analysis - Length of effectiveness...........................................................................................30
Sensitivity Analysis - Take-up rates of programs......................................................................................31
TAKE-UP RATE AMONGST GPS)...............................................................................................................................33
Summary of results...........................................................................................................................................33
5 DISCUSSION...................................................................................................................................................34
Healthy Public Policy......................................................................................................................................34
Building Partnerships.......................................................................................................................................35
Effectiveness and evidence: biomedical, clinical & social behaviour considerations.......................35
Behaviour modification....................................................................................................................................38
Portfolio Investment........................................................................................................................................40
Otherdiseases....................................................................................................................................................41
Equity...................................................................................................................................................................41
REFERENCES.....................................................................................................................................................43
Appendixa.......................................................................................................................................................54
Appendixb.......................................................................................................................................................55
Appendixc.......................................................................................................................................................65
More intriguing information
1. The name is absent2. The name is absent
3. AGRICULTURAL TRADE LIBERALIZATION UNDER NAFTA: REPORTING ON THE REPORT CARD
4. The name is absent
5. The name is absent
6. Competition In or For the Field: Which is Better
7. Der Einfluß der Direktdemokratie auf die Sozialpolitik
8. Food Prices and Overweight Patterns in Italy
9. Equity Markets and Economic Development: What Do We Know
10. Electricity output in Spain: Economic analysis of the activity after liberalization